Since the advent of immune checkpoint inhibitors in 2010, cancer treatment has transformed by using the immune system to combat cancer. This has allowed many advanced melanoma patients to achieve long-term remission, signifying a major shift from traditional treatments. However, the anticipated broader impact has not occurred; many patients still lack access to immunotherapy. Innovations are stifled by scientific, economic, and cultural barriers. Although we've exploited initial treatment options, there are still numerous unexplored immune evasion strategies that hold promise for future therapies.
The first breakthrough targeted just one of cancer's many immune-evading tricks, yet there are likely other equally powerful approaches waiting to be discovered.
The breakneck pace of innovation in cancer treatment has slowed drastically, where most cancer patients still do not receive immunotherapy.
Collection
[
|
...
]